Following the fraught departure of its former CEO, biotech’s biggest and most influential lobby BIO is in the process of reinventing itself — and its recently appointed chair Ted Love is set to play a key role in working to improve the industry’s image while developing an effective strategy in response to new drug pricing legislation and for diversifying the organization. Love — who previously served as CEO of the sickle cell disease drugmaker Global Blood Therapeutics before it was sold to Pfizer in 2022 — will have his work cut out for him when it comes to retaining member organizations: Both Pfizer and UCB left the lobby group in recent months.
Industry
Location
-
San Francisco, Calif.
